Narcotic Bowel Syndrome

Abstract

Introduction: Narcotic Bowel Syndrome (NBS) is a complication associated with chronic opioid use, characterized by the paradoxical worsening of abdominal pain despite the maintenance or escalation of opioid analgesic therapy. Although it represents an important cause of chronic abdominal pain among patients receiving long-term opioid treatment, it remains frequently underdiagnosed and is often mistaken for functional gastrointestinal disorders or other abdominal diseases. The lack of awareness of this syndrome contributes to unnecessary diagnostic investigations, recurrent hospitalizations, and inappropriate escalation of opioid therapy, perpetuating a cycle of pain and drug dependence. In this context, understanding its pathophysiological mechanisms, clinical manifestations, and therapeutic strategies is essential for early recognition and improved clinical outcomes.

Objective: To analyze the available scientific evidence regarding the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of Narcotic Bowel Syndrome in patients receiving chronic opioid therapy.

Methodology: This integrative literature review was conducted using the PubMed/MEDLINE, Scopus, Web of Science, Embase, SciELO, and Virtual Health Library (VHL) databases. The descriptors "Narcotic Bowel Syndrome," "Opioid-Induced Hyperalgesia," "Chronic Abdominal Pain," and "Opioids" were combined using the Boolean operators AND and OR. Articles published between 2007 and 2026, available in full text in English, Portuguese, and Spanish, were included. Editorials, letters to the editor, conference abstracts, experimental animal studies, duplicate publications, and studies not directly related to the topic were excluded.

Results: The reviewed studies demonstrated that Narcotic Bowel Syndrome is closely associated with the development of opioid-induced hyperalgesia, central sensitization, and alterations in pain modulation, which are responsible for the progressive worsening of abdominal pain during continuous opioid use. Diagnosis remains predominantly clinical and depends on excluding other organic causes of abdominal pain, frequently resulting in extensive and repeated diagnostic investigations. The main factors associated with the development of the syndrome included prolonged opioid use, progressive escalation of opioid doses, and chronic painful conditions.

Conclusions: Narcotic Bowel Syndrome remains an underdiagnosed condition in clinical practice despite its significant impact on patient morbidity and healthcare utilization. Early recognition of the syndrome, combined with gradual opioid tapering and multidisciplinary management, may improve clinical outcomes, reduce unnecessary diagnostic procedures, and promote a more rational use of opioid analgesic therapy.